Inhibition of human dyskerin as a new approach to target ribosome biogenesis

Area of Science:

• Biochemistry
• Molecular Biology
• Computational Chemistry

Background:

• Dyskerin (DKC1 gene product) is vital for ribosome biogenesis and telomerase stabilization.
• Targeting these processes is a strategy for cancer drug development.
• Identifying novel targets that disrupt hyperactive cancer cell functions is crucial.

Purpose of the Study:

• To computationally identify small molecules that inhibit dyskerin's catalytic activity.
• To validate the potential of modulating dyskerin's pseudouridylation activity for therapeutic purposes.

Main Methods:

• In silico techniques were employed for compound selection and analysis of ligand binding modes within the human dyskerin catalytic site.
• A novel, optimized fast real-time PCR assay was developed to detect dyskerin pseudouridylation activity in vitro.

Main Results:

• The study reports the first computational identification of small molecules capable of inhibiting dyskerin catalytic activity.
• Experimental validation confirmed that dyskerin's pseudouridylation activity can be modulated by small molecule agents.
• Computational and experimental approaches successfully identified potential dyskerin inhibitors.

Conclusions:

• The findings present a proof of principle for targeting dyskerin's pseudouridylation activity with small molecules.
• This research suggests an alternative therapeutic strategy focused on the ribosome biogenesis pathway for cancer treatment.
• The study highlights the utility of computational tools combined with experimental validation in drug discovery.